Ovarian cancer

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Retrieved on: 
Saturday, March 16, 2024
Diagnosis, Ovarian cancer, MIRV, Mutation, Health, BRCA, Science, Disease, Partnership, Patient, Education, Glomus tumor, Roche, Biomarker, Neoplasm, Research, Cancer, EOC, Recombinant DNA, Woman, HRP, PARP, TTD, Fibroadenoma, HRD, Mirvetuximab soravtansine, BRCA2, Recurrence, LH, BRCA1, ADP, Pharmaceutical industry

BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).

Key Points: 
  • The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).
  • Labcorp researchers conducted two studies to generate further evidence of the value of comprehensive genomic profiling to drive guideline-compliant testing that enables increased patient access to targeted therapies for improved outcomes.
  • When combined, the results of BRCA and HRD testing can determine which patients are most likely to benefit from treatment with poly-ADP ribose polymerase (PARP) inhibitors.
  • "This research emphasizes the power of comprehensive biomarker testing in advancing the treatment of ovarian cancer.

The Foundation for Women's Cancer is Calling on Everyone Connected to Women's Health to Move Today for More Tomorrows

Retrieved on: 
Saturday, March 16, 2024
Ovarian cancer, Friends, Ginger, Organization, Assistant, Education, Social media, Research, SGO, FWC, Society, Woman, Cancer, Gynecologic Oncology (journal), Platinum, Movement, Pharmaceutical industry

CHICAGO, March 16, 2024 /PRNewswire-PRWeb/ -- The Foundation for Women's Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), is excited to announce the commencement of Move4Her 2024! Move4Her is the FWC's signature fundraising campaign that helps power research, education, and awareness of the five gynecologic (gyn) cancers. As part of Move4Her, individuals and teams are asked to commit five minutes or more each day to movement and encourage their friends and loved ones to support them on their Move4Her journey. Individuals and teams choose the activity or adventure of their choice to drive their movement, and will receive Move4Her resources to help spread awareness of their Move4Her commitment. In its fifth consecutive year, Move4Her is challenging participants to raise more awareness and accelerate the momentum towards a common goal – ending the five gyn cancers – cervical, ovarian, uterine/endometrial, vaginal and vulvar cancer.

Key Points: 
  • Move4Her is the FWC's signature fundraising campaign that helps power research, education, and awareness of the five gynecologic (gyn) cancers.
  • Ultimately, Move4Her participants fund life-changing programs that support better outcomes – more tomorrows now and for future generations, through donations and fundraising efforts.
  • "It is an absolute honor to be supported by the Move4Her participants and the Foundation for Women's Cancer.
  • Follow the FWC on its social media platforms Twitter , Instagram and Facebook for exciting updates throughout the year.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on: 
Thursday, March 14, 2024
Ovarian cancer, Immunotherapy, Patient, History, Lutetium (177Lu) oxodotreotide, IND, Cancer, NVS, NUVB, NCI, Novartis, Science, Colorectal cancer, Risk, American Cancer Society, FOLFIRINOX, PDAC, Pancreatic Cancer Action Network, Safety, Immune system, Interim, University, Translational research, Survival rate, Disease, Clinical professor, Associate, Tumor microenvironment, Death, TSX, Pancreatic cancer, Sunnybrook Health Sciences Centre, ACRS, FDA, DCP, Diagnosis, Entrepreneurship, Environment, Physician, Triple-negative breast cancer, Mortality, News, PROC, DDC, Hereditary nonpolyposis colorectal cancer, Optimism, ONC, Pharmaceutical industry

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB). 

Key Points: 
  • There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
  • "Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
  • It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
  • Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Caris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancer

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, PR, UCS, NCI, Ovarian cancer, Promise, OSCC, Survival, EEC, Exome sequencing, Glomus tumor, TMB, Patient, Neoplasm, NGS, Biomarker, Research, DNA, RNA, Cancer, AI, SGO, Carcinosarcoma, MD, Endometrial cancer, Medicine, Abstract, POA, Prognosis, Poster, ETS, Medical imaging

IRVING, Texas, March 13, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present three studies across multiple gynecological tumor types at the 2024 SGO Annual Meeting on Women's Cancer, March 16-18, 2024, in San Diego. The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene, to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene
    "We are proud to return and present an array of precision oncology research at this year's SGO Annual Meeting.
  • The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) criteria classify four molecular subtypes of endometrial tumors (ET).
  • Poster and abstract summaries highlighting the Caris research presented at SGO 2024 will be available onsite at Caris' booth (#601).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Friday, March 8, 2024
Eli Lilly, Therapy, Research, Enzyme, CDX, PARP, Drug development, DRP, ADP, Interim, Biomarker, Ovarian cancer, Administration, Patient, Oncology, G&A, Appointment, Cancer, Pharmaceutical industry

The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.

Key Points: 
  • The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.
  • Announced leadership changes and strategic advisory engagement:
    Appointment of co-founder Thomas H. Jensen as Interim Chief Executive Officer in December 2023.
  • With nearly two decades at Allarity Therapeutics, Jensen brings extensive experience and a deep understanding of the company’s DRP® to his new role.
  • Net Loss from Operations: Net Loss from Operations was $17.1 million for 2023, compared to $34 million for 2022.

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

Retrieved on: 
Thursday, March 7, 2024
SAN, KRON, AACR, Lung cancer, Safety, Genentech, Ovarian cancer, Patient, Multiple myeloma, CDK9, IND, KAT, Cancer, Pharmaceutical industry

SAN MATEO, Calif., and CAMBRIDGE, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the Company’s pipeline, including the ongoing phase 1/2 study of KB-0742 following the review of additional positive preliminary safety and efficacy data. This plan positions the Company to maximize the potential of KB-0742, an inhibitor of CDK9, by exploring an extended dosing schedule while also continuing to progress KB-9558, a p300 KAT inhibitor, through ongoing IND-enabling studies and into the clinic, and its discovery efforts and collaborations. The Company expects these efforts, which include a 21% reduction in force, will extend cash runway into the second half of 2026.

Key Points: 
  • The Company expects these efforts, which include a 21% reduction in force, will extend cash runway into the second half of 2026.
  • The Company has reported target engagement, tumor regressions, and an acceptable safety profile at 60mg dosed three-days-on, four-days-off.
  • KB-0742 cleared 80mg three-days-on, four-days-off and the Company expects to publish this data in addition to the 60mg expansion mid-year.
  • Pending the completion of IND-enabling studies in 2024, the Company expects to commence a first-in-human study in multiple myeloma in 2025.

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024
Online, Carboplatin, CRDF, SAN, Cancer, Progression-free survival, PDX, Cetuximab, EGFR, Bev, Carcinoma, FOLFIRI, PLK1, AACR, Bevacizumab, RAS, Cisplatin, Ovarian cancer, Abstract, Paclitaxel, Patient, Clinical trial, Mutation, Publication, Vaccine

“In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.

Key Points: 
  • “In RAS-mutated mCRC, we are showing the underlying mechanism through which the combination of onvansertib and bevacizumab targets the hypoxia response pathway.
  • We believe this mechanism explains the strong clinical results we have seen in both our Phase 1b/2 and ONSEMBLE second-line RAS-mutated mCRC clinical trials.
  • The abstracts are available on the AACR Online Program and will be published in the online Proceedings of the AACR.
  • Following presentation, the posters will be posted to the " Scientific Presentations " section of the Cardiff Oncology website.

Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Neoplasm, Synovial sarcoma, Safety, Stomach, CSP, Ovarian cancer, PM, Patient, Cancer, Vaccine

Details on the poster presentation are as follows:

Key Points: 
  • Details on the poster presentation are as follows:
    Session details: PO.IM01.13 - Adoptive Cell Therapies 1: Tumor Antigen-Specific T-cells and TCR-T, Sunday, April 7, 1:30 PM - 5:00 PM local time
    The work to be presented shows that recombinant T cell receptor engineered T cells (rTCR-T cells), when armored and enhanced by the PD1-41BB CSP, exhibit superior TCR-T cell functionality and safety as well as a favorable safety profile, revealing the strong potential for improving treatment of cancer patients suffering from advanced solid tumor malignancies.
  • The Company is planning a first-in-human trial for MDG1015, a TCR-T therapy incorporating the CSP in gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma with IND/CTA filing targeted for 2H 2024.
  • MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by the PD1-41BB CSP.

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 5, 2024
Research, FDA, Platinum, Exercise, ARID1A, Mayo Clinic, Ovarian cancer, Clinical professor, Cholangiocarcinoma, PIPE

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2023 was an eventful year for Nuvectis as we continued to make important strides with our two clinical-stage drug candidates, NXP800 and NXP900.

Key Points: 
  • Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "2023 was an eventful year for Nuvectis as we continued to make important strides with our two clinical-stage drug candidates, NXP800 and NXP900.
  • Cash, and cash equivalents were $19.1 million as of December 31, 2023, compared to $20.0 million as of December 31, 2022.
  • Net loss for the 2023 fiscal year included $4.7 million in non-cash stock-based compensation and $2.3 million in one-time non-recurring expenses.
  • Interest income was $0.6 million for the year ended December 31, 2023, compared to $0.1 million for the year ended December 31, 2022, an increase of $0.5 million.